According to 21Shares, the Dogecoin ETF’s launch marks a pivotal move in the journey of Dogecoin ($DOGE) from just a meme coin to a robust institutional asset.According to 21Shares, the Dogecoin ETF’s launch marks a pivotal move in the journey of Dogecoin ($DOGE) from just a meme coin to a robust institutional asset.

21Shares Launches Physically-Backed Dogecoin ETF to Offer $DOGE Exposure

dogecoin-15 main

21Shares, a renowned crypto ETPs issuer, is launching the exclusive Dogecoin ETF. This launch underscores a landmark development in the mainstream adoption of meme coins. As 21Shares disclosed in its official press release, the latest Dogecoin ETF, which is physically backed, offers $DOGE exposure. Hence, the investors can access $DOGE without any need to directly hold it.

21Shares Introduces New Dogecoin ETF ‘$TDOG’ to Bolster Global Crypto Adoption

The 21Shares Dogecoin ETF will operate under the ticker symbol $TDOG at eligible brokerages. The launch denotes a significant shift in the way the conventional investors perceive digital assets. Once discredited as a joke, the meme token Dogecoin ($DOGE) has gradually taken a leading position among the top crypto assets. Hence, based on its low fees and rapid transfer speed, $DOGE has gained noteworthy recognition in the crypto market.

Apart from that, the active and strong community of Dogecoin also plays a crucial role in driving its wider visibility and adoption. Simultaneously, the cultural relevance of Dogecoin permits the onboarding of newly entering consumers into the crypto market, often underscoring a 1st entry spot for retail users. Over time, the respective accessibility has delivered meaningful use cases, taking into account merchant acceptance among the top brands like AMC Theatres and Tesla.

Keeping this in view, by offering exposure to $DOGE in a regulated manner, 21Shares is poised to connect conventional financial markets and crypto communities. This approach goes in line with the platform’s wider strategy of broadening institutional-scale digital asset access. Going beyond market performance, the community ethos of Dogecoin remains its critical characteristic. In this respect, the “Do Only Good Everyday” philosophy gets the credit for inspiring charitable initiatives as well as social impact campaigns across the globe.

$DOGE ETF Underscores Rising Crypto Integration into Mainstream Finance

According to 21Shares, the Dogecoin ETF’s launch marks a pivotal move in the journey of Dogecoin from just an internet meme-inspired token to a robust institutional asset. Although the risks are still there, the product highlights the rising trend of incorporating community-led crypto assets into the broader financial landscape. Overall, this signals the commencement of an exclusive chapter for Dogecoin ($DOGE) as well as the wider crypto sector.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26